This multicenter , randomized , double-blind , placebo-controlled , parallel-group trial evaluated patients ( n = 177 ) with elevated low-density lipoprotein cholesterol ( LDL-C ) ( 130 to 220 mg/dl ) , who were stratified by baseline triglycerides ( not elevated [ < 150 mg/dl ] or elevated [ 150 - < 400 mg/dl ] ) and randomized to receive 40 , 80 , or 120 mg of ETC-1002 or placebo once daily for 12 weeks .
